Search Follow us

addex therapeutics

1 - 12 of 29
Sort by: popularity | newest
Page  2 3  of 3 | Next

Edison healthcare quarterly: A boost for allergy immunotherapy

Sector Commentary: | Pharmaceuticals & healthcare | 05 Mar 2014


Futura Medical

Edison healthcare quarterly: Immuno-oncology 2: The combos come

Sector Commentary: | Pharmaceuticals & healthcare | 06 Nov 2013


Addex Therapeutics

Termination of coverage

Update | Pharmaceuticals & healthcare | 27 Aug 2013

Edison Investment Research is terminating coverage on Addex Therapeutics (ADXN). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Trillium Therapeutics

Edison healthcare quarterly: Immunotherapy takes centre stage

Sector Commentary: | Pharmaceuticals & healthcare | 31 Jul 2013


Addex Therapeutics

Dipraglurant data supports orphan disease focus

Update | Pharmaceuticals & healthcare | 19 Apr 2013

Positive preclinical data for dipraglurant in dystonia supports progression into a Phase II study for rare dystonias in H113. Phase II results (Q413), if positive, could trigger a larger Phase IIb trial (2014). Addex continues to target a dipraglurant partnership for Parkinson's disease (PD), which may be informed by upcoming Phase II results (Q213) for Novartis's competing mGlu5 inhibitor (AFQ056). While Addex is currently financed to end-2013, potential deals and/or financings could extend the cash runway. A planned NASDAQ listing (timing tbc) in our view, could be a prelude to a financing.

Merrimack Pharmaceuticals

Edison healthcare quarterly: German (drug) reformation

Sector Commentary: | Pharmaceuticals & healthcare | 10 Apr 2013


Addex Therapeutics

New orphan disease focus

Outlook | Pharmaceuticals & healthcare | 05 Mar 2013

Addex is now focused on developing its clinical pipeline for rare diseases and will significantly reduce discovery activities. In 2013 Addex will complete a pilot Phase II study of dipraglurant for rare dystonia and target a partnership for the Parkinson's disease (PD) indication. It will also complete a Phase I study of ADX71441 for Charcot-Marie-Tooth (CMT) disease, as well as select a clinical candidate for the mGlu4 PAM programme in multiple sclerosis. While Addex is currently financed to end-2013, potential licensing deals and/or financings could extend the cash runway.


Edison healthcare quarterly: Boom times for US biotech

Sector Commentary: | Pharmaceuticals & healthcare | 07 Dec 2012


Addex Therapeutics

Targeting deals and data in 2013

Update | Pharmaceuticals & healthcare | 04 Dec 2012

Buoyed by its recent fund-raising and pipeline progress, Addex is entering a critical period in which it hopes to secure a partnership for its lead programme, dipraglurant, for PD-LID and other CNS indications. Encouraging Phase II results for lead partnered drug, JNJ-40411813, being advanced for the treatment of negative symptoms in schizophrenia, raise the prospect of further positive clinical data in 2013 and/or initiation of new clinical studies by J&J. Addex's internal pipeline should also progress in 2013 with the initiation of Phase I trials for ADX71441.

Cytos Biotechnology

Edison healthcare quarterly: Crisis? What crisis?

Sector Commentary: | Pharmaceuticals & healthcare | 30 Aug 2012


Addex Therapeutics

Lilly issues may give Addex a boost

Update | Pharmaceuticals & healthcare | 30 Jul 2012

Addex has seen an unexpected boost to the prospects for its lead partnered product, JNJ-40411813, as a result of a trial setback reported recently with Lilly's pomaglumetad methionil, a mechanistically-close competitor. The news may allow Janssen Pharmaceuticals, Addex's partner, to catch up with a rival that had hitherto been several years ahead. Both products aim to up-regulate mGluR2, but Lilly's is an orthosteric mGluR2/3 agonist, while Addex's is a more selective mGluR2 PAM. Meanwhile J&J is completing its own Phase II study in schizophrenia and is starting a Phase II study in anxiety co-morbid with depression.

Addex Therapeutics

J&J anxiety go-ahead

Update | Pharmaceuticals & healthcare | 06 Jun 2012

J&J has recently disclosed plans to conduct a Phase II study on the Addex-licensed mGluR2 PAM, JNJ-40411813, in anxiety co-morbid with depression. J&J is concurrently completing its Phase II study of the compound in schizophrenia, with data expected in early/mid Q3. Meanwhile, Addex has cut back its workforce to extend its cash reach while it seeks a partner for dipraglurant, for which positive Phase II data in PD-LID were recently reported.